RAPID MICRO BIOSYSTEMS INC-A (RPID) Stock Fundamental Analysis

NASDAQ:RPID • US75340L1044

3.89 USD
-0.08 (-2.02%)
Last: Feb 20, 2026, 08:03 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

2

Taking everything into account, RPID scores 2 out of 10 in our fundamental rating. RPID was compared to 58 industry peers in the Life Sciences Tools & Services industry. RPID may be in some trouble as it scores bad on both profitability and health. RPID is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year RPID has reported negative net income.
  • In the past year RPID has reported a negative cash flow from operations.
  • In the past 5 years RPID always reported negative net income.
  • RPID had a negative operating cash flow in each of the past 5 years.
RPID Yearly Net Income VS EBIT VS OCF VS FCFRPID Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

  • With a Return On Assets value of -52.47%, RPID is not doing good in the industry: 86.21% of the companies in the same industry are doing better.
  • The Return On Equity of RPID (-99.91%) is worse than 79.31% of its industry peers.
Industry RankSector Rank
ROA -52.47%
ROE -99.91%
ROIC N/A
ROA(3y)-38.74%
ROA(5y)-42.64%
ROE(3y)-47.91%
ROE(5y)-72.28%
ROIC(3y)N/A
ROIC(5y)N/A
RPID Yearly ROA, ROE, ROICRPID Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 1K 2K 3K

1.3 Margins

  • The Gross Margin of RPID (7.72%) is worse than 89.66% of its industry peers.
  • RPID does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 7.72%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RPID Yearly Profit, Operating, Gross MarginsRPID Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -100 -200 -300

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • RPID does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RPID has been increased compared to 1 year ago.
  • The number of shares outstanding for RPID has been increased compared to 5 years ago.
  • Compared to 1 year ago, RPID has a worse debt to assets ratio.
RPID Yearly Shares OutstandingRPID Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RPID Yearly Total Debt VS Total AssetsRPID Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -6.53, we must say that RPID is in the distress zone and has some risk of bankruptcy.
  • RPID's Altman-Z score of -6.53 is on the low side compared to the rest of the industry. RPID is outperformed by 79.31% of its industry peers.
  • RPID has a Debt/Equity ratio of 0.43. This is a healthy value indicating a solid balance between debt and equity.
  • Looking at the Debt to Equity ratio, with a value of 0.43, RPID is in line with its industry, outperforming 41.38% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Altman-Z -6.53
ROIC/WACCN/A
WACC10.89%
RPID Yearly LT Debt VS Equity VS FCFRPID Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

  • RPID has a Current Ratio of 4.23. This indicates that RPID is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 4.23, RPID is in the better half of the industry, outperforming 65.52% of the companies in the same industry.
  • A Quick Ratio of 2.95 indicates that RPID has no problem at all paying its short term obligations.
  • RPID has a Quick ratio of 2.95. This is comparable to the rest of the industry: RPID outperforms 55.17% of its industry peers.
Industry RankSector Rank
Current Ratio 4.23
Quick Ratio 2.95
RPID Yearly Current Assets VS Current LiabilitesRPID Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an nice 9.82% over the past year.
  • The Revenue has grown by 16.63% in the past year. This is quite good.
  • Measured over the past years, RPID shows a quite strong growth in Revenue. The Revenue has been growing by 11.18% on average per year.
EPS 1Y (TTM)9.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)16.63%
Revenue growth 3Y6.49%
Revenue growth 5Y11.18%
Sales Q2Q%3.08%

3.2 Future

  • The Earnings Per Share is expected to grow by 9.25% on average over the next years. This is quite good.
  • Based on estimates for the next years, RPID will show a very strong growth in Revenue. The Revenue will grow by 21.98% on average per year.
EPS Next Y6.03%
EPS Next 2Y8.88%
EPS Next 3Y10.09%
EPS Next 5Y9.25%
Revenue Next Year19.19%
Revenue Next 2Y20.43%
Revenue Next 3Y22.33%
Revenue Next 5Y21.98%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RPID Yearly Revenue VS EstimatesRPID Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 20M 40M 60M 80M
RPID Yearly EPS VS EstimatesRPID Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 -0.5 -1 -1.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RPID. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RPID. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RPID Price Earnings VS Forward Price EarningsRPID Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RPID Per share dataRPID EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.88%
EPS Next 3Y10.09%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RPID does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RAPID MICRO BIOSYSTEMS INC-A

NASDAQ:RPID (2/20/2026, 8:03:33 PM)

3.89

-0.08 (-2.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-07
Earnings (Next)02-27
Inst Owners57.19%
Inst Owner Change0.29%
Ins Owners4%
Ins Owner Change10.63%
Market Cap172.40M
Revenue(TTM)30.52M
Net Income(TTM)-44.29M
Analysts84
Price Target8.16 (109.77%)
Short Float %0.47%
Short Ratio0.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-4.27%
Min EPS beat(2)-4.49%
Max EPS beat(2)-4.04%
EPS beat(4)2
Avg EPS beat(4)0.82%
Min EPS beat(4)-4.49%
Max EPS beat(4)6.22%
EPS beat(8)4
Avg EPS beat(8)1.35%
EPS beat(12)7
Avg EPS beat(12)2.26%
EPS beat(16)8
Avg EPS beat(16)0.3%
Revenue beat(2)1
Avg Revenue beat(2)0.19%
Min Revenue beat(2)-0.85%
Max Revenue beat(2)1.23%
Revenue beat(4)3
Avg Revenue beat(4)2.67%
Min Revenue beat(4)-0.85%
Max Revenue beat(4)7.03%
Revenue beat(8)7
Avg Revenue beat(8)4.21%
Revenue beat(12)10
Avg Revenue beat(12)6.25%
Revenue beat(16)11
Avg Revenue beat(16)2.63%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)1.11%
EPS NQ rev (3m)1.11%
EPS NY rev (1m)0%
EPS NY rev (3m)-1.02%
Revenue NQ rev (1m)1.34%
Revenue NQ rev (3m)1.34%
Revenue NY rev (1m)0.46%
Revenue NY rev (3m)2.81%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 5.65
P/FCF N/A
P/OCF N/A
P/B 3.89
P/tB 3.89
EV/EBITDA N/A
EPS(TTM)-1.01
EYN/A
EPS(NY)-0.88
Fwd EYN/A
FCF(TTM)-0.87
FCFYN/A
OCF(TTM)-0.85
OCFYN/A
SpS0.69
BVpS1
TBVpS1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.47%
ROE -99.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 7.72%
FCFM N/A
ROA(3y)-38.74%
ROA(5y)-42.64%
ROE(3y)-47.91%
ROE(5y)-72.28%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.36
Health
Industry RankSector Rank
Debt/Equity 0.43
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.7%
Cap/Sales 2.8%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.23
Quick Ratio 2.95
Altman-Z -6.53
F-Score3
WACC10.89%
ROIC/WACCN/A
Cap/Depr(3y)112.45%
Cap/Depr(5y)118.7%
Cap/Sales(3y)17.47%
Cap/Sales(5y)14.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y6.03%
EPS Next 2Y8.88%
EPS Next 3Y10.09%
EPS Next 5Y9.25%
Revenue 1Y (TTM)16.63%
Revenue growth 3Y6.49%
Revenue growth 5Y11.18%
Sales Q2Q%3.08%
Revenue Next Year19.19%
Revenue Next 2Y20.43%
Revenue Next 3Y22.33%
Revenue Next 5Y21.98%
EBIT growth 1Y12.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.84%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.03%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y20.14%
OCF growth 3YN/A
OCF growth 5YN/A

RAPID MICRO BIOSYSTEMS INC-A / RPID FAQ

Can you provide the ChartMill fundamental rating for RAPID MICRO BIOSYSTEMS INC-A?

ChartMill assigns a fundamental rating of 2 / 10 to RPID.


Can you provide the valuation status for RAPID MICRO BIOSYSTEMS INC-A?

ChartMill assigns a valuation rating of 0 / 10 to RAPID MICRO BIOSYSTEMS INC-A (RPID). This can be considered as Overvalued.


Can you provide the profitability details for RAPID MICRO BIOSYSTEMS INC-A?

RAPID MICRO BIOSYSTEMS INC-A (RPID) has a profitability rating of 0 / 10.


What is the expected EPS growth for RAPID MICRO BIOSYSTEMS INC-A (RPID) stock?

The Earnings per Share (EPS) of RAPID MICRO BIOSYSTEMS INC-A (RPID) is expected to grow by 6.03% in the next year.